1
|
Peretz Y, He Z, Shi Y, Yassine-Diab B, Goulet JP, Bordi R, Filali-Mouhim A, Loubert JB, El-Far M, Dupuy FP, Boulassel MR, Tremblay C, Routy JP, Bernard N, Balderas R, Haddad EK, Sékaly RP. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog 2012; 8:e1002840. [PMID: 22916009 PMCID: PMC3420930 DOI: 10.1371/journal.ppat.1002840] [Citation(s) in RCA: 115] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2011] [Accepted: 06/20/2012] [Indexed: 12/27/2022] Open
Abstract
Chronic viral infections lead to persistent CD8 T cell activation and functional exhaustion. Expression of programmed cell death-1 (PD-1) has been associated to CD8 T cell dysfunction in HIV infection. Herein we report that another negative regulator of T cell activation, CD160, was also upregulated on HIV-specific CD8 T lymphocytes mostly during the chronic phase of infection. CD8 T cells that expressed CD160 or PD-1 were still functional whereas co-expression of CD160 and PD-1 on CD8 T cells defined a novel subset with all the characteristics of functionally exhausted T cells. Blocking the interaction of CD160 with HVEM, its natural ligand, increased HIV-specific CD8 T cell proliferation and cytokine production. Transcriptional profiling showed that CD160−PD-1+CD8 T cells encompassed a subset of CD8+ T cells with activated transcriptional programs, while CD160+PD-1+ T cells encompassed primarily CD8+ T cells with an exhausted phenotype. The transcriptional profile of CD160+PD-1+ T cells showed the downregulation of the NFκB transcriptional node and the upregulation of several inhibitors of T cell survival and function. Overall, we show that CD160 and PD-1 expressing subsets allow differentiating between activated and exhausted CD8 T cells further reinforcing the notion that restoration of function will require multipronged approaches that target several negative regulators. HIV infection is widely known to cause generalized immune activation and immune exhaustion ultimately leading to HIV disease progression. Several studies have suggested over the years that the accumulation of inhibitory signalling proteins on the surface of responding cells is linked to immune exhaustion in HIV. It has become paramount to distinguish functionally exhausted CD8 T cells from activated HIV-specific CD8 T cells because both cell types have different fates. Using specific cell surface markers, we were able to identify these different cell types and show that HIV-infected patients accumulate dysfunctional CD8 T cells over time. Importantly, we show that this dysfunction is reversible.
Collapse
Affiliation(s)
- Yoav Peretz
- Caprion/ImmuneCarta Services, Montreal, Quebec, Canada
- Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Hôpital St-Luc, Montreal, Quebec, Canada
- Laboratoire d'Immunologie, Département de Microbiologie et d'Immunologie, Université de Montreal, Montreal, Quebec, Canada
| | - Zhong He
- Vaccine & Gene Therapy Institute Florida, Port St. Lucie, Florida, United States of America
| | - Yu Shi
- Vaccine & Gene Therapy Institute Florida, Port St. Lucie, Florida, United States of America
| | - Bader Yassine-Diab
- Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Hôpital St-Luc, Montreal, Quebec, Canada
- Laboratoire d'Immunologie, Département de Microbiologie et d'Immunologie, Université de Montreal, Montreal, Quebec, Canada
| | - Jean-Philippe Goulet
- Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Hôpital St-Luc, Montreal, Quebec, Canada
- Laboratoire d'Immunologie, Département de Microbiologie et d'Immunologie, Université de Montreal, Montreal, Quebec, Canada
| | - Rebeka Bordi
- Vaccine & Gene Therapy Institute Florida, Port St. Lucie, Florida, United States of America
| | - Ali Filali-Mouhim
- Vaccine & Gene Therapy Institute Florida, Port St. Lucie, Florida, United States of America
| | - Jean-Baptiste Loubert
- Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Hôpital St-Luc, Montreal, Quebec, Canada
- Laboratoire d'Immunologie, Département de Microbiologie et d'Immunologie, Université de Montreal, Montreal, Quebec, Canada
| | - Mohamed El-Far
- Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Hôpital St-Luc, Montreal, Quebec, Canada
- Laboratoire d'Immunologie, Département de Microbiologie et d'Immunologie, Université de Montreal, Montreal, Quebec, Canada
| | - Franck P. Dupuy
- Vaccine & Gene Therapy Institute Florida, Port St. Lucie, Florida, United States of America
| | - Mohamed Rachid Boulassel
- Immunodeficiency Service and Division of Hematology, Royal Victoria Hospital, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
| | - Cécile Tremblay
- Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Hôpital St-Luc, Montreal, Quebec, Canada
- Laboratoire d'Immunologie, Département de Microbiologie et d'Immunologie, Université de Montreal, Montreal, Quebec, Canada
| | - Jean-Pierre Routy
- Immunodeficiency Service and Division of Hematology, Royal Victoria Hospital, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
| | - Nicole Bernard
- Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada
| | - Robert Balderas
- BD Biosciences, San Diego, California, United States of America
| | - Elias K. Haddad
- Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Hôpital St-Luc, Montreal, Quebec, Canada
- Laboratoire d'Immunologie, Département de Microbiologie et d'Immunologie, Université de Montreal, Montreal, Quebec, Canada
- Vaccine & Gene Therapy Institute Florida, Port St. Lucie, Florida, United States of America
| | - Rafick-Pierre Sékaly
- Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Hôpital St-Luc, Montreal, Quebec, Canada
- Laboratoire d'Immunologie, Département de Microbiologie et d'Immunologie, Université de Montreal, Montreal, Quebec, Canada
- Vaccine & Gene Therapy Institute Florida, Port St. Lucie, Florida, United States of America
- Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada
- Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada
- Institut National de la Santé et de la Recherche Médicale U743, CRCHUM, Université de Montreal, Montreal, Quebec, Canada
- * E-mail:
| |
Collapse
|